CareDx (CDNA) Aktienübersicht
CareDx, Inc. bietet Lösungen zur Verbesserung der Ergebnisse für Transplantationspatienten und zur Förderung der Organgesundheit in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 6/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für CDNA festgestellt.
CDNA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.676.1% unterbewertet intrinsischer Abschlag
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCareDx, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$21.44 |
| 52-Wochen-Hoch | US$23.24 |
| 52-Wochen-Tief | US$10.96 |
| Beta | 2.49 |
| 1 Monat Veränderung | 21.34% |
| 3 Monate Veränderung | 10.12% |
| 1 Jahr Veränderung | 39.31% |
| 3 Jahre Veränderung | 156.46% |
| 5 Jahre Veränderung | -66.61% |
| Veränderung seit IPO | 114.40% |
Aktuelle Nachrichten und Updates
Analyse-Update • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Seeking Alpha • Apr 18
CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Summary CareDx is a leading precision medicine company specializing in transplant diagnostics, recently divesting its lab products portfolio for $170 million to focus on core testing services. CDNA demonstrates solid revenue growth and improving gross margins, but faces stiff competition from Natera, limited differentiation, and ongoing regulatory headwinds. Despite positive cash flow and a low debt/equity ratio, risks include declining R&D spending, falling book value, insider selling, and policy uncertainty that could impact revenue. I maintain a Hold rating on CDNA, viewing shares as attractive below $18, but prefer Natera for growth-oriented investors given its stronger momentum and market position. Read the full article on Seeking AlphaRecent updates
Analyse-Update • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Seeking Alpha • Apr 18
CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Summary CareDx is a leading precision medicine company specializing in transplant diagnostics, recently divesting its lab products portfolio for $170 million to focus on core testing services. CDNA demonstrates solid revenue growth and improving gross margins, but faces stiff competition from Natera, limited differentiation, and ongoing regulatory headwinds. Despite positive cash flow and a low debt/equity ratio, risks include declining R&D spending, falling book value, insider selling, and policy uncertainty that could impact revenue. I maintain a Hold rating on CDNA, viewing shares as attractive below $18, but prefer Natera for growth-oriented investors given its stronger momentum and market position. Read the full article on Seeking AlphaAnalyse-Update • Apr 13
CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.
Analyse-Update • Mar 30
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.Analyse-Update • Mar 16
CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.Analyse-Update • Mar 02
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.Analyse-Update • Feb 16
CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.
Analyse-Update • Feb 01
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.Analyse-Update • Jan 18
CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.Analyse-Update • Jan 04
CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).Analyse-Update • Dec 17
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).Analyseartikel • Nov 29
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 25% gain in the last month alone...Analyseartikel • Nov 12
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
CareDx, Inc ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...Analyseartikel • Sep 19
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Those holding CareDx, Inc ( NASDAQ:CDNA ) shares would be relieved that the share price has rebounded 28% in the last...Analyseartikel • Aug 27
Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Key Insights The projected fair value for CareDx is US$10.87 based on 2 Stage Free Cash Flow to Equity Current share...Analyse-Update • Aug 15
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.Analyseartikel • Jul 23
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
The CareDx, Inc ( NASDAQ:CDNA ) share price has fared very poorly over the last month, falling by a substantial 32...Analyseartikel • May 02
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
Key Insights The projected fair value for CareDx is US$20.92 based on 2 Stage Free Cash Flow to Equity Current share...
Neue Analyse • Mar 24
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.Seeking Alpha • Mar 13
CareDx: Some Litigation Clouds Have Cleared
Summary CareDx, Inc. has cleared up some litigation and legal challenges since I last looked at this diagnostic concern last summer. The company continues to post solid revenue growth and has a rock-solid balance sheet. FY2024 saw progress on numerous fronts, and CDNA delivered margin increases and a massive increase in adjusted EBITDA. An updated analysis around CareDx, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Mar 11
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
We didn't see CareDx, Inc's ( NASDAQ:CDNA ) stock surge when it reported robust earnings recently. We decided to have a...Seeking Alpha • Dec 30
CareDx: Too Risky For Me
Summary CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile. Management changes and negative employee reviews indicate potential internal instability, casting doubt on future company performance despite their innovative products. Despite strong gross margins and a solid balance sheet, CareDx's inability to turn a profit and questionable capital allocation methods make it a sell. Read the full article on Seeking AlphaAnalyseartikel • Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
CareDx, Inc ( NASDAQ:CDNA ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Sep 29
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Summary CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. Despite ongoing legal disputes with Natera, revised processes may protect future AlloSure revenues. CDNA's valuation is high, but its expanding revenues and recent insurance coverage wins justify a "Buy" rating for investors aware of inherent biotech risks. Read the full article on Seeking AlphaAnalyseartikel • Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 34% in the last...Seeking Alpha • Jul 15
CareDx: Benefiting From Some Certainty
Summary Today, we circle back to diagnostic testing concern CareDx, Inc for the first time in 2024. The stock has moved up some 60% since the company delivered better than expected quarterly results in early May. The company has appointed a new CEO and seen some certainty around a key patent litigation lawsuit so far this year as well. Can the rally continue, or is the stock overdue for some profit taking? An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Apr 27
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
CareDx, Inc ( NASDAQ:CDNA ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...Analyseartikel • Mar 02
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
CareDx, Inc ( NASDAQ:CDNA ) shareholders would be excited to see that the share price has had a great month, posting a...Analyseartikel • Dec 27
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking...Analyseartikel • Dec 27
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 26% in the last...Aktionärsrenditen
| CDNA | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 3.0% | 1.3% | 2.2% |
| 1Y | 39.3% | 42.0% | 31.1% |
Rendite im Vergleich zur Industrie: CDNA unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 41.9% erzielte.
Rendite vs. Markt: CDNA übertraf den Markt US, der im vergangenen Jahr eine Rendite von 30.6 erzielte.
Preisvolatilität
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: CDNA hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CDNADie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. bietet Lösungen zur Verbesserung der Ergebnisse für Transplantationspatienten und zur Förderung der Organgesundheit in den Vereinigten Staaten und international. Das Unternehmen bietet AlloSure Kidney, eine Lösung für von Spendern stammende zellfreie DNA (dd-cfDNA) für Nierentransplantationspatienten; AlloMap Heart, eine Lösung für die Erstellung von Genexpressionsprofilen für Herztransplantationspatienten; AlloSure Heart, eine dd-cfDNA-Lösung für Herztransplantationspatienten; und AlloSure Lung, eine dd-cfDNA-Lösung für Lungentransplantationspatienten. Es bietet auch HeartCare an, das Informationen über verschiedene biologische Prozesse liefert, wie z.B.
CareDx, Inc.'s Grundlagenzusammenfassung
| CDNA grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.08b |
| Gewinn(TTM) | -US$8.19m |
| Umsatz(TTM) | US$412.82m |
2.7x
Kurs-Umsatz-Verhältnis-135.2x
Kurs-Gewinn-Verhältnis Ist CDNA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CDNA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$412.82m |
| Kosten der Einnahmen | US$128.45m |
| Bruttogewinn | US$284.37m |
| Sonstige Ausgaben | US$292.56m |
| Gewinn | -US$8.19m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.16 |
| Bruttomarge | 68.88% |
| Nettogewinnspanne | -1.98% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich CDNA auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/07 05:37 |
| Aktienkurs zum Tagesende | 2026/05/07 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CareDx, Inc. wird von 14 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |